Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Frank Cornell

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2015
Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management ApproachRobert Frank Cornell, Parameswaran Hari, William R Drobyski
BMJ Case Reports|November 27, 2019
Rare case of non-producer variant of plasma cell dyscrasias with circulating plasma cellsSukesh Manthri, Rabia Zafar, Robert Frank Cornell, et al.
British Journal of Haematology|July 6, 2018
Second primary malignancy after multiple myeloma-population trends and cause-specific mortalityLuciano J Costa, Kelly N Godby, Saurabh Chhabra, et al.
Frontiers in Oncology|March 16, 2019
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory TherapyRobert Frank Cornell, Samuel Z Goldhaber, Brian G Engelhardt, et al.
American Journal of Hematology|April 26, 2019
Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b studyNoa Biran, David Siegel, Jesus G Berdeja, et al.
Case Reports in Endocrinology|January 24, 2014
Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiencyRobert Frank Cornell, Daniel F Kelly, Gal Bordo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2017
Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain AmyloidosisOluchi Oke, Tarsheen Sethi, Stacey Goodman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 29, 2013
Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myelomaRobert Frank Cornell, Parameswaran Hari, Mei-Jie Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple MyelomaDan T Vogl, David Dingli, Robert Frank Cornell, et al.
BMC Cancer|September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyGabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2015
Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management ApproachRobert Frank Cornell, Parameswaran Hari, William R Drobyski
BMJ Case Reports|November 27, 2019
Rare case of non-producer variant of plasma cell dyscrasias with circulating plasma cellsSukesh Manthri, Rabia Zafar, Robert Frank Cornell, et al.
British Journal of Haematology|July 6, 2018
Second primary malignancy after multiple myeloma-population trends and cause-specific mortalityLuciano J Costa, Kelly N Godby, Saurabh Chhabra, et al.
Frontiers in Oncology|March 16, 2019
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory TherapyRobert Frank Cornell, Samuel Z Goldhaber, Brian G Engelhardt, et al.
American Journal of Hematology|April 26, 2019
Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b studyNoa Biran, David Siegel, Jesus G Berdeja, et al.
Case Reports in Endocrinology|January 24, 2014
Chemotherapy-induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiencyRobert Frank Cornell, Daniel F Kelly, Gal Bordo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2017
Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain AmyloidosisOluchi Oke, Tarsheen Sethi, Stacey Goodman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 29, 2013
Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myelomaRobert Frank Cornell, Parameswaran Hari, Mei-Jie Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple MyelomaDan T Vogl, David Dingli, Robert Frank Cornell, et al.
BMC Cancer|September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyGabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Pageof 2